Agios Pharmaceuticals, Inc. (AGIO) Stock Price

AGIOStock

$33.90−15.88%52W

Market Cap$2.02B

P/E2.61x

PEG Ratio—

Div yield—

Beta0.63

AGIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)7.19%

Price vs S&P 500 (4W)-12.36%

VGM Score59.37

P/E Ratio (Annual)2.61x

Book Value / Share (Quarterly)$17.21

P/TBV (Annual)1.13x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)55.97%

Cash Flow / Share (Quarterly)$-6.13

Price vs S&P 500 (YTD)7.95%

Gross Margin (TTM)91.99%

Net Profit Margin (TTM)-418.24%

EPS (TTM)$-7.01

10-Day Avg Trading Volume1.00M

EPS Excl Extra (TTM)$-7.01

Revenue Growth (5Y)4.67%

EPS (Annual)$-7.12

ROI (Annual)-34.60%

Gross Margin (Annual)88.26%

Net Profit Margin (5Y Avg)-445.03%

Cash / Share (Quarterly)$10.36

Revenue Growth QoQ (YoY)259.25%

P/E Normalized (Annual)2.61x

ROA (Last FY)-31.82%

Revenue Growth TTM (YoY)140.58%

EBITD / Share (TTM)$-7.73

ROE (5Y Avg)13.77%

Operating Margin (TTM)-466.78%

Cash Flow / Share (Annual)$-6.46

P/B Ratio1.95x

P/B Ratio (Quarterly)2.15x

Net Income / Employee (Annual)$-765,800

EV / Revenue (TTM)19.31x

ROA (TTM)-33.06%

EV / EBITDA (TTM)3.00x

EPS Incl Extra (Annual)$-7.12

Current Ratio (Annual)11.46x

Quick Ratio (Quarterly)9.14x

3-Month Avg Trading Volume1.16M

52-Week Price Return-15.88%

Revenue / Employee (TTM)$182,400

Tangible BV / Share (Quarterly)$15.87

P/S Ratio (Annual)36.98x

Asset Turnover (Annual)0.04x

52-Week High$46.00

Operating Margin (5Y Avg)-532.96%

EPS Excl Extra (Annual)$-7.12

CapEx CAGR (5Y)-21.96%

Tangible BV CAGR (5Y)24.00%

26-Week Price Return18.43%

Quick Ratio (Annual)10.52x

13-Week Price Return13.37%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.22x

Enterprise Value$1.90B

Revenue / Share Growth (5Y)0.19%

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)28.77%

Revenue / Employee (Annual)$100,200

Inventory Turnover (Annual)0.21x

Pretax Margin (Annual)-765.89%

Cash / Share (Annual)$14.62

3-Month Return Std Dev60.31%

Gross Margin (5Y Avg)90.54%

Net Income / Employee (TTM)$-763,100

ROE (Last FY)-34.60%

EPS Basic Excl Extra (Annual)$-7.12

Receivables Turnover (TTM)6.74x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-7.01

Receivables Turnover (Annual)7.36x

ROI (TTM)-35.67%

P/S Ratio (TTM)20.32x

Pretax Margin (5Y Avg)-421.16%

Revenue / Share (Annual)$0.93

Tangible BV / Share (Annual)$20.00

Price vs S&P 500 (52W)-34.19%

Year-to-Date Return19.91%

5-Day Price Return-5.12%

EPS Normalized (Annual)$-7.12

ROA (5Y Avg)12.81%

Net Profit Margin (Annual)-764.01%

Month-to-Date Return8.73%

Cash Flow / Share (TTM)$-3.84

EBITD / Share (Annual)$-8.05

EPS Growth (3Y)-24.03%

Operating Margin (Annual)-873.87%

ROI (5Y Avg)13.76%

EPS Basic Excl Extra (TTM)$-7.01

P/TBV (Quarterly)1.41x

P/B Ratio (Annual)1.33x

Inventory Turnover (TTM)0.26x

Pretax Margin (TTM)-419.27%

Book Value / Share (Annual)$20.41

Price vs S&P 500 (13W)10.58%

Beta0.63x

P/FCF (Annual)69.77x

Revenue / Share (TTM)$1.65

ROE (TTM)-35.67%

52-Week Low$22.24

vGradeC

gGradeB

mGradeC

vgmGradeC

AGIO Earnings Surprise History

Q2 25-1.93est. -1.75

Q3 25-1.78est. -1.90

Q4 25-1.85est. -1.95

Q1 26-1.69est. -1.79

Q2 26-1.69est. -1.67

AGIO Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.06

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
AGIOAgios Pharmaceuticals, Inc.	C	B	C	$33.90
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals develops small-molecule medicines for rare hematologic diseases through cellular metabolism pathways. Its lead product, Pyrukynd (mitapivat), is a pyruvate kinase activator for hemolytic anemias, with additional pipeline candidates targeting sickle cell disease and myelodysplastic syndrome-associated anemia. The company addresses significant unmet medical needs in rare blood disorders.